Detail akcie Sopharma AD Sofia, Ordinary, MiFID Eligible Security, Warsaw Stock Exchange online

Business Summary: Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Sopharma AD revenues increased 25% to BGN644.7M. Net income increased 36% to BGN40.3M. Revenues reflect Sales of Goods increase of 28% to BGN554.9M, Sales of Products increase of 15% to BGN85.6M, Other Sales increase of 32% to BGN590K. Net income benefited from Equity in Affiliates increase from BGN4.6M to BGN11.5M (income), Foreign Currency Exchange Rate Gains increase from BGN79K to BGN2M (income).